- Corporate Officers - R
- Rhodes Jason P
Insider Trading History of Rhodes Jason P
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Rhodes Jason P since 2014.
This trader's CIK number is 1577014.
At the time of last reporting, Rhodes Jason P was the Officer of Dyne Therapeutics, Inc.. (stock ticker symbol DYN).
Also see all insider trading activities at Dyne Therapeutics, Inc..
Note that in the past
Rhodes Jason P also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Generation Bio Co. (GBIO) by Rhodes Jason P
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2021 | GBIO | 0 | $0 | 699,949 | $18,325,656 | 0 | $0 |
Yearly summary of insider trading at Epizyme, Inc. (EPZM) by Rhodes Jason P
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2014 | EPZM | 0 | $0 | 235,000 | $6,383,508 | 373,000 | $598,260 |
Yearly summary of insider trading at Replimune Group, Inc. (REPL) by Rhodes Jason P
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2021 | REPL | 0 | $0 | 5,558 | $256,446 | 0 | $0 |
| 2020 | REPL | 0 | $0 | 390,396 | $17,459,207 | 0 | $0 |
| 2019 | REPL | 1,100,000 | $14,971,000 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Dyne Therapeutics, Inc. (DYN) by Rhodes Jason P
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2024 | DYN | 0 | $0 | 1,866,095 | $44,505,537 | 0 | $0 |
| 2022 | DYN | 934,581 | $10,000,016 | 0 | $0 | 0 | $0 |
Insider trading activities at 4 companies by Rhodes Jason P:
1. Generation Bio Co. (GBIO)
2. Epizyme, Inc. (EPZM)
3. Replimune Group, Inc. (REPL)
4. Dyne Therapeutics, Inc. (DYN)
Table 1. Insider trading of Generation Bio Co. (GBIO) by Rhodes Jason P
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2021-09-27 | GBIO | Sale | 51,389 | 25.70 | 1,320,697 |
| 2021-09-29 | GBIO | Sale | 16,586 | 24.59 | 407,849 |
| 2021-09-28 | GBIO | Sale | 13,113 | 25.24 | 330,972 |
| 2021-09-22 | GBIO | Sale | 30,617 | 25.89 | 792,704 |
| 2021-09-23 | GBIO | Sale | 75,465 | 26.27 | 1,982,616 |
| 2021-09-24 | GBIO | Sale | 28,916 | 25.84 | 747,160 |
| 2021-06-24 | GBIO | Sale | 31,008 | 26.08 | 808,688 |
| 2021-06-23 | GBIO | Sale | 62,609 | 25.39 | 1,589,329 |
| 2021-06-22 | GBIO | Sale | 58,577 | 24.98 | 1,463,253 |
| 2021-06-21 | GBIO | Sale | 63,892 | 24.97 | 1,595,383 |
| 2021-04-12 | GBIO | Sale | 74,124 | 26.34 | 1,952,426 |
| 2021-04-13 | GBIO | Sale | 43,145 | 25.31 | 1,091,999 |
| 2021-04-14 | GBIO | Sale | 23,413 | 26.59 | 622,551 |
| 2021-04-08 | GBIO | Sale | 43,550 | 28.68 | 1,249,231 |
| 2021-04-09 | GBIO | Sale | 43,681 | 27.96 | 1,221,320 |
| 2021-04-07 | GBIO | Sale | 39,864 | 28.84 | 1,149,478 |
Table 2. Insider trading of Epizyme, Inc. (EPZM) by Rhodes Jason P
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2014-09-22 | EPZM | Option Ex | 44,000 | .51 | 22,440 |
| 2014-09-02 | EPZM | Option Ex | 42,000 | 2.07 | 86,940 |
| 2014-09-02 | EPZM | Sale | 30,000 | 33.63 | 1,008,869 |
| 2014-08-04 | EPZM | Sale | 30,000 | 29.66 | 889,650 |
| 2014-08-04 | EPZM | Option Ex | 42,000 | 2.07 | 86,940 |
| 2014-07-07 | EPZM | Sale | 30,000 | 33.03 | 990,990 |
| 2014-07-07 | EPZM | Option Ex | 42,000 | 1.55 | 65,100 |
| 2014-06-02 | EPZM | Option Ex | 42,000 | 2.02 | 85,050 |
| 2014-06-02 | EPZM | Sale | 30,000 | 22.75 | 682,590 |
| 2014-05-05 | EPZM | Sale | 30,000 | 21.53 | 645,840 |
| 2014-05-05 | EPZM | Option Ex | 42,000 | 2.02 | 85,050 |
| 2014-04-07 | EPZM | Option Ex | 35,000 | .51 | 17,850 |
| 2014-04-07 | EPZM | Sale | 25,000 | 20.05 | 501,199 |
| 2014-02-10 | EPZM | Option Ex | 70,000 | 2.02 | 141,750 |
| 2014-02-10 | EPZM | Sale | 50,000 | 29.25 | 1,462,500 |
| 2014-01-06 | EPZM | Option Ex | 14,000 | .51 | 7,140 |
| 2014-01-06 | EPZM | Sale | 10,000 | 20.19 | 201,870 |
Table 3. Insider trading of Replimune Group, Inc. (REPL) by Rhodes Jason P
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2021-01-26 | REPL | Sale | 5,558 | 46.14 | 256,446 |
| 2020-12-18 | REPL | Sale | 4,319 | 41.95 | 181,182 |
| 2020-12-17 | REPL | Sale | 11,535 | 42.00 | 484,470 |
| 2020-12-15 | REPL | Sale | 40,819 | 43.20 | 1,763,380 |
| 2020-12-16 | REPL | Sale | 12,675 | 42.13 | 533,997 |
| 2020-12-14 | REPL | Sale | 37,659 | 43.43 | 1,635,530 |
| 2020-12-11 | REPL | Sale | 31,636 | 43.62 | 1,379,962 |
| 2020-12-10 | REPL | Sale | 34,391 | 43.50 | 1,496,111 |
| 2020-12-07 | REPL | Sale | 67,890 | 46.12 | 3,131,358 |
| 2020-12-08 | REPL | Sale | 108,256 | 46.49 | 5,033,037 |
| 2020-12-09 | REPL | Sale | 41,216 | 44.16 | 1,820,180 |
| 2019-11-18 | REPL | Buy | 1,100,000 | 13.61 | 14,971,000 |
Table 4. Insider trading of Dyne Therapeutics, Inc. (DYN) by Rhodes Jason P
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2024-11-14 | DYN | Sale | 782 | 33.10 | 25,884 |
| 2024-03-01 | DYN | Sale | 46,534 | 30.05 | 1,398,346 |
| 2024-02-26 | DYN | Sale | 248,219 | 23.79 | 5,903,888 |
| 2024-02-27 | DYN | Sale | 368,699 | 24.53 | 9,044,186 |
| 2024-02-28 | DYN | Sale | 190,920 | 25.04 | 4,780,636 |
| 2024-02-23 | DYN | Sale | 196,928 | 22.70 | 4,470,265 |
| 2024-02-22 | DYN | Sale | 119,360 | 22.66 | 2,704,697 |
| 2024-02-21 | DYN | Sale | 184,501 | 22.79 | 4,204,777 |
| 2024-02-15 | DYN | Sale | 177,906 | 24.16 | 4,299,098 |
| 2024-02-16 | DYN | Sale | 162,707 | 23.14 | 3,765,039 |
| 2024-02-20 | DYN | Sale | 169,539 | 23.05 | 3,908,721 |
| 2022-12-12 | DYN | Buy | 934,581 | 10.70 | 10,000,016 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Rhodes Jason P
(Officer of Dyne Therapeutics, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.